We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byManuel Stokoe
Modified about 1 year ago
When Using DOPPS Slides
DOPPS Slide Use Guidelines
Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and parathyroid hormone: the Dialysis Outcomes and Practice Patterns Study (DOPPS)
Table 1. Study sample characteristics at baseline (1)
Table 1. Study sample characteristics (2)
Serum Calcium by country and DOPPS phase
Serum Phosphorus by country and DOPPS phase
PTH by country and DOPPS phase
All-cause and cardiovascular mortality risk associated with baseline serum calcium
All-cause and cardiovascular mortality risk associated with baseline serum phosphorus
All-cause and cardiovascular mortality risk associated with baseline PTH
Risk for all-cause and cardiovascular mortality associated with DOPPS-derived risk categories for serum calcium, phosphorus and PTH
Patient mortality risk associated with 10% more facility patients within each serum PO 4 category versus reference category (3.6-5.0 mg/dL)
Risk of all-cause mortality associated with combinations of baseline serum phosphorus and calcium categories by PTH level
Recommended mineral metabolism marker levels in Stage 5 CKD according to different professional organizations, and lowest mortality risk categories observed in the DOPPS
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
1 Antonio Bellasi, MD Medical manager Genzyme, Italy Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD)
Depression As a Predictor of Mortality and Hospitalization Among Hemodialysis Patients in the United States and Europe.
Dietary Phosphorus Restriction for Control of PTH in CKD Guideline 4.1. Restriction of Dietary Phosphorus in Patients with CKD Dietary phosphorus should.
Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:
Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
Hyperphosphataemia in chronic kidney disease Support for education and learning for children and young people’s renal services: slide set March 2013 NICE.
Lynda K. Ball, MSN, RN, CNN Quality Improvement Director Northwest Renal Network Improving Sub-Optimal Hemoglobins October 14, 2010.
RELATIONSHIP BETWEEN PARATHYROID HORMONE, VITAMIN-D, CALCIUM AND PHOSPHORUS IN CKD Neeraja Kunireddy, Priscilla Abraham Chandran, Sree Bhushan Raju, M.Noorjahan.
KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD)
Vitamin D deficiency and anemia in early chronic kidney disease 2010/05/18 R4 이완수 2010.
Title Authors Introduction Text, text, text, text, text, text Background Information Text, text, text, text, text, text Observations Text, text, text,
Introduction Data Statistical Methods Table 1: Prevalence of Prior Hip Fracture and Incidence of New Hip Fractures and Fractures of Any Type.
A R ETROSPECTIVE R EVIEW OF THE IMPLEMENTATION OF A VITAMIN D SUPPLEMENTATION POLICY IN CHILDREN WITH CHRONIC RENAL IMPAIRMENT. Sandra H. Geraghty, Clinical.
West Midlands Guidelines for managing CKD Mineral and Bone Disorders in Haemodialysis Patients
Comparison of Asymmetric DimethylArginine Levels and Coronary Artery Calcifications in Different Stages of Chronic Kidney Disease and Kidney Transplantation.
Network 11 Quality Update Chris Singer, MAN, RN, CNN December 4, 2008.
Chronic Kidney Disease-Mineral and Bone Disorder Introduction Chronic kidney disease is commonly linked with mineral and bone disorder (CKD-MBD). This.
Effect of cinacalcet on bone markers in a maintenance haemodialysis patient Solenn Pelletier, MD and Denis Fouque, MD, PhD Hôpital E. Herriot Lyon, France.
Secondary Hyperparathyroidism in CKD: Usefulness of VDR Agonists Reference: Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin d.
Vitamin D metabolism in the pathogenesis of renal osteodystrophy and secondary hyperparathyroidism Geoffrey Block MD Director of Clinical Research Denver.
Dietary Issues in Renal Complications Ulrich Wahl, Tamworth, 2010.
The SYMPHONY Trial Reference Reddan DN, et al. Renal function, concomitant medication use and outcomes following acute coronary syndromes. Nephrol Dial.
Chronic Kidney Disease-Related Mineral and Bone Disorder: Public Health Problem Kerry Willis PhD National Kidney Foundation.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
Secondary Hyperparathyroidism in Chronic Kidney Disease 2009/11/13 신장내과 R3 이완수.
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
LINEE GUIDA, KDIGO E DIALISI PERITONEALE
SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ﬀ ects of lowering LDL cholesterol with simvastatin plus.
J OURNAL C LUB EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events – EVOLVE NEJM Dec 2012 Yuvaraj Thangaraj, M.D. Nephrology Fellow Division.
Rayaldee ® - calcifediol Manufacturer: OPKO Ireland Global Holdings Ltd. FDA Approval Date: June 21, 2016.
Dialysis Outcomes and Practice Patterns Study Impact of Dialysis Prescriptions and Practices on Outcomes Friedrich K. Port, MD, MS Arbor Research Collaborative.
Chapter 28: Vitamin D: Production, Metabolism, Mechanism of Action, and Clinical Requirements Daniel Bikle, John Adams, and Sylvia Christakos.
Biochemical Test Serum Calcium – to confirm increase in calcium as action of the parathyrod hormone – Normal: 8.5 mg/dL – Normal ionized: 4.4 – 5.2 mg/dL.
Dialysis Outcomes and Practice Patterns Study Trends from the Dialysis Outcomes Practice Patterns Study-DOPPS in Vascular Access Use in Haemodialysis.
The FRACTURE Study (Ongoing). Source West SL, Lok CE, Jamal SA. Fracture Risk Assessment in Chronic Kidney Disease, Prospective Testing Under Real World.
NKF-KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease UPDATE OF HEMOGLOBIN TARGET Am.J.Kidney.Dis.
Analysis of Risk Factors for Early Access Failure of AVF in Patients on Hemodialysis 경희 대학교 의과대학 내과학교실 문수연, 박병조, 이향이, 정경환, 김정희, 이상호, 이태원, 임천규, 김명재.
Which Beta-Blocker is Best for Patients with Heart Failure? Summary and Comment by Joel M. Gore, MD Published in Journal Watch Cardiology December 17,
Title of the study. Principal investigator and co workers names Organization/College name.
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.
The mortality associated with body size and muscle mass, fat mass and abdominal obesity in patients receiving hemodialysis Date: 2012/12/21 實習生：余萍 指導老師：蕭佩珍營養師.
Jadoul, et al. Clin J Am Soc Nephrol 2012; 7(5): When Using DOPPS Slides We welcome the use of DOPPS slides as we value the distribution of our.
PARATHYROID HORMONE, HYPERPARATHYROIDISM CKD, & PTH ASSAYS David Plaut & Shanti Narayanan Summer, 2012.
Guidelines for the Early Management of Diabetic Ketoacidosis in Children Guidelines for the Early Management of Diabetic Ketoacidosis in Children Michael.
Chapter 72 Chapter 72 Calcium in the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.
© 2017 SlidePlayer.com Inc. All rights reserved.